Top

Published in:

Open Access 01-12-2016 | Research

Non-unions treated with bone morphogenic protein 7: introducing the quantitative measurement of human serum cytokine levels as promising tool in evaluation of adjunct non-union therapy

Authors: Arash Moghaddam, Lisa Breier, Patrick Haubruck, Daniel Bender, Bahram Biglari, Andreas Wentzensen, Gerald Zimmermann

Published in: Journal of Inflammation | Issue 1/2016

Abstract

Background

In this study we sought to determine if application of bone morphogenic protein 7 (BMP-7) promotes physiological bone healing of non-unions and to investigate if serum cytokine analysis may serve as a promising tool in the analysis of adjunct non-union therapy. Therefore we analyzed the influence of BMP-7 application on the serum cytokine expression patterns on patients with impaired bone healing compared to patients that showed proper bone healing.

Methods

Our study involved analyzing blood samples from 208 patients with long bone fractures together with patients that subsequently developed non-unions. From this large pool, 15 patients with atrophic non-union were matched to 15 patients with atrophic non-union treated with local application of BMP-7 as well as normal bone healing. Changes in the cytokine expression patterns were monitored during the 1st, 2nd, 4th, 8th, 12th and 52nd week. The patients were followed both clinically and radiologically for the entire duration of the study. Serum cytokine expression levels of transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) were analyzed and compared.

Results

Serum expression of TGF-β were nearly parallel in all three groups, however serum concentrations were significantly higher in patients with proper bone healing and those treated with BMP-7 than in patients with non-unions (p < 0.05). bFGF serum concentrations increased initially in patients with proper bone healing and in those treated with BMP-7. Afterwards, values decreased; bFGF serum concentrations in the BMP-7 group were significantly higher than in the other groups (p < 0.05). PDGF serum concentration levels were nearly parallel in all groups, serum concentrations were significantly higher in patients with proper bone healing and those treated with BMP-7 than in patients with non-unions (p < 0.05).

Conclusion

Treatment with BMP-7 in patients with former non-unions led to similar cytokine expression patterns after treatment as those found in patients with proper bone healing. Our results suggest that treatment with BMP-7 promote healing of non-unions. Furthermore, quantitative measurement of serum cytokine expression is a promising tool for evaluating the effectiveness of additional non-union therapies such as adjunct application of growth factors.

Schmidmaier G, Moghaddam A. Long bone nonunion. Z Orthop Unfall. 2015;153(6):659–76. doi:10.1055/s-0035-1558259.CrossRefPubMed

Rodriguez-Merchan EC, Forriol F. Nonunion: general principles and experimental data. Clin Orthop Relat Res. 2004;419:4–12.CrossRefPubMed

Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011;93(23):2227–36. doi:10.2106/JBJS.J.01513.CrossRefPubMed

Janicki P, Schmidmaier G. What should be the characteristics of the ideal bone graft substitute? Combining scaffolds with growth factors and/or stem cells. Injury. 2011;42 Suppl 2:S77–81. doi:10.1016/j.injury.2011.06.014.CrossRefPubMed

Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury. 2005;36 Suppl 3:S20–7. doi:10.1016/j.injury.2005.07.029.CrossRefPubMed

Shah P, Keppler L, Rutkowski J. Bone morphogenic protein: an elixir for bone grafting--a review. Eur J Oral Implantol. 2012;38(6):767–78. doi:10.1563/AAID-JOI-D-10-00196.CrossRef

Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev. 2010;6:CD006950. doi:10.1002/14651858.CD006950.pub2.PubMed

TRACP. 5b and CTX as osteological markers of delayed fracture healing. 2010.

Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of compromised fracture healing. J Am Acad Orthop Surg. 2012;20(5):273–82. doi:10.5435/JAAOS-20-05-273.CrossRefPubMed

10.

den Boer FC, Wippermann BW, Blokhuis TJ, Patka P, Bakker FC, Haarman HJ. Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow. J Orthop Res. 2003;21(3):521–8. doi:10.1016/S0736-0266(02)00205-X.CrossRef

11.

Zimmermann G, Henle P, Kusswetter M, Moghaddam A, Wentzensen A, Richter W, et al. TGF-beta1 as a marker of delayed fracture healing. Bone. 2005;36(5):779–85. doi:10.1016/j.bone.2005.02.011.CrossRefPubMed

12.

Weiss S, Henle P, Bidlingmaier M, Moghaddam A, Kasten P, Zimmermann G. Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing. Growth Horm IGF Res. 2008;18(3):205–12. doi:10.1016/j.ghir.2007.09.002.CrossRefPubMed

13.

Weiss S, Zimmermann G, Pufe T, Varoga D, Henle P. The systemic angiogenic response during bone healing. Arch Orthop Trauma Surg. 2009;129(7):989–97. doi:10.1007/s00402-008-0777-5.CrossRefPubMed

14.

Moghaddam A, Muller U, Roth HJ, Wentzensen A, Grutzner PA, Zimmermann G. TRACP 5b and CTX as osteological markers of delayed fracture healing. Injury. 2011;42(8):758–64. doi:10.1016/j.injury.2010.11.017.CrossRefPubMed

15.

Moghaddam A, Weiss S, Wolfl CG, Schmeckenbecher K, Wentzensen A, Grutzner PA, et al. Cigarette smoking decreases TGF-b1 serum concentrations after long bone fracture. Injury. 2010;41(10):1020–5. doi:10.1016/j.injury.2010.03.014.CrossRefPubMed

16.

Moghaddam A1, Weiss S, Wölfl CG, Schmeckenbecher K, Wentzensen A, Grützner PA, et al. Cigarette smoking decreases TGF-β1 serum concentrations after long bone fracture, (2010).

17.

Bosemark P, Perdikouri C, Pelkonen M, Isaksson H, Tagil M. The masquelet induced membrane technique with BMP and a synthetic scaffold can heal a rat femoral critical size defect. J Orthop Res. 2015;33(4):488–95. doi:10.1002/jor.22815.CrossRefPubMed

18.

Moghaddam-Alvandi A, Zimmermann G, Buchler A, Elleser C, Biglari B, Grutzner PA, et al. Results of nonunion treatment with bone morphogenetic protein 7 (BMP-7). Unfallchirurg. 2012;115(6):518–26. doi:10.1007/s00113-011-2100-0.CrossRefPubMed

19.

Karger C, Kishi T, Schneider L, Fitoussi F, Masquelet AC. Treatment of posttraumatic bone defects by the induced membrane technique. Orthop Traumatol Surg Res. 2012;98(1):97–102. doi:10.1016/j.otsr.2011.11.001.CrossRefPubMed

20.

Pelissier P, Masquelet AC, Bareille R, Pelissier SM, Amedee J. Induced membranes secrete growth factors including vascular and osteoinductive factors and could stimulate bone regeneration. J Orthop Res. 2004;22(1):73–9. doi:10.1016/s0736-0266(03)00165-7.CrossRefPubMed

21.

Masquelet AC, Begue T. The concept of induced membrane for reconstruction of long bone defects. The Orthopedic clinics of North America. 2010;41(1):27–37; table of contents. doi:10.1016/j.ocl.2009.07.011.

22.

Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand Suppl. 1998;283:2–37.PubMed

23.

Patil AS, Sable RB, Kothari RM. An update on transforming growth factor-beta (TGF-beta): sources, types, functions and clinical applicability for cartilage/bone healing. J Cell Physiol. 2011;226(12):3094–103. doi:10.1002/jcp.22698.CrossRefPubMed

24.

Tekari A, Luginbuehl R, Hofstetter W, Egli RJ. Transforming growth factor Beta signaling is essential for the autonomous formation of cartilage-like tissue by expanded chondrocytes. PLoS One. 2015;10(3):e0120857. doi:10.1371/journal.pone.0120857.PubMedCentralCrossRefPubMed

25.

Wang CJ, Yang KD, Ko JY, Huang CC, Huang HY, Wang FS. The effects of shockwave on bone healing and systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions. Nitric oxide. 2009;20(4):298–303. doi:10.1016/j.niox.2009.02.006.CrossRefPubMed

26.

Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg. 2007;77(8):626–31. doi:10.1111/j.1445-2197.2007.04175.x.CrossRefPubMed

27.

Takemoto R, Forman J, Taormina DP, Egol KA. No advantage to rhBMP-2 in addition to autogenous graft for fracture nonunion. Orthopedics. 2014;37(6):e525–30. doi:10.3928/01477447-20140528-51.CrossRefPubMed

28.

Borrelli Jr J, Prickett WD, Ricci WM. Treatment of nonunions and osseous defects with bone graft and calcium sulfate. Clin Orthop Relat Res. 2003;411:245–54. doi:10.1097/01.blo.0000069893.31220.6f.CrossRefPubMed

29.

Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res. 2002;17(3):513–20. doi:10.1359/jbmr.2002.17.3.513.CrossRefPubMed

30.

Giannoudis PV, Kanakaris NK, Dimitriou R, Gill I, Kolimarala V, Montgomery RJ. The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res. 2009;467(12):3239–48. doi:10.1007/s11999-009-0846-2.PubMedCentralCrossRefPubMed

31.

Moghaddam A, Zietzschmann S, Bruckner T, Schmidmaier G. Treatment of atrophic tibia non-unions according to ‘diamond concept’: Results of one- and two-step treatment. Injury. 2015;46 Suppl 4:S39–50. doi:10.1016/S0020-1383(15)30017-6.CrossRefPubMed

32.

Niikura T, Hak DJ, Reddi AH. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res. 2006;24(7):1463–71. doi:10.1002/jor.20182.CrossRefPubMed

33.

Tim CR, Bossini PS, Kido HW, Malavazi I, von Zeska Kress MR, Carazzolle MF, et al. Effects of low-level laser therapy on the expression of osteogenic genes during the initial stages of bone healing in rats: a microarray analysis. Lasers Med Sci. 2015;30(9):2325–33. doi:10.1007/s10103-015-1807-5.CrossRefPubMed

34.

Buttner M, Moller S, Keller M, Huster D, Schiller J, Schnabelrauch M, et al. Over-sulfated chondroitin sulfate derivatives induce osteogenic differentiation of hMSC independent of BMP-2 and TGF-beta1 signalling. J Cell Physiol. 2013;228(2):330–40. doi:10.1002/jcp.24135.CrossRefPubMed

35.

Gerstenfeld LC1, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation, (2003).

36.

Binder H, Eipeldauer S, Gregori M, Hochtl-Lee L, Thomas A, Tiefenboeck TM, et al. The difference between growth factor expression after single and multiple fractures: preliminary results in human fracture healing. Dis Markers. 2015;2015:203136. doi:10.1155/2015/203136.PubMedCentralCrossRefPubMed

37.

Glueck M, Gardner O, Czekanska E, Alini M, Stoddart MJ, Salzmann GM, et al. Induction of osteogenic differentiation in human mesenchymal stem cells by crosstalk with osteoblasts. BioRes Open Access. 2015;4(1):121–30. doi:10.1089/biores.2015.0002.PubMedCentralCrossRefPubMed

38.

Caplan AI, Correa D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J Orthop Res. 2011;29(12):1795–803. doi:10.1002/jor.21462.CrossRefPubMed

39.

Tan HB, Giannoudis PV, Boxall SA, McGonagle D, Jones E. The systemic influence of platelet-derived growth factors on bone marrow mesenchymal stem cells in fracture patients. BMC med. 2015;13:6. doi:10.1186/s12916-014-0202-6.PubMedCentralCrossRefPubMed

40.

Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am. 2008;90 Suppl 1:48–54. doi:10.2106/JBJS.G.01231.CrossRefPubMed

41.

Tyndall WA, Beam HA, Zarro C, O’Connor JP, Lin SS. Decreased platelet derived growth factor expression during fracture healing in diabetic animals. Clin Orthop Relat Res. 2003;408:319–30.CrossRefPubMed

42.

Younger A, Wing K, Penner M, Cresswell M. A study to evaluate the safety of platelet-derived growth factor for treatment of osteochondral defects of the talus. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2015. doi:10.1007/s00167-015-3549-0.

43.

Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;15(2):203–8.CrossRefPubMed

44.

Chen T, Gomez AW, Zuo Y, Li X, Zhang Z, Li Y et al. Osteogenic potential and synergistic effects of growth factors delivered from a bionic composite system. Journal of biomedical materials research Part A. 2015. doi:10.1002/jbm.a.35605

45.

Saadeh PB, Mehrara BJ, Steinbrech DS, Spector JA, Greenwald JA, Chin GS, et al. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells. Endocrinology. 2000;141(6):2075–83. doi:10.1210/endo.141.6.7502.CrossRefPubMed

46.

Hanada K, Dennis JE, Caplan AI. Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. J Bone Miner Res. 1997;12(10):1606–14. doi:10.1359/jbmr.1997.12.10.1606.CrossRefPubMed

47.

Kawaguchi H, Nakamura K, Tabata Y, Ikada Y, Aoyama I, Anzai J, et al. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J Clin Endocrinol Metab. 2001;86(2):875–80. doi:10.1210/jcem.86.2.7199.CrossRefPubMed

48.

Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone. 2004;34(3):402–11. doi:10.1016/j.bone.2003.11.014.CrossRefPubMed

49.

Nelson ER, Huang Z, Ma T, Lindsey D, Jacobs C, Smith RL, et al. New bone formation by murine osteoprogenitor cells cultured on corticocancellous allograft bone. J Orthop Res. 2008;26(12):1660–4. doi:10.1002/jor.20676.CrossRefPubMed

50.

Quarto N, Longaker MT. FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng. 2006;12(6):1405–18. doi:10.1089/ten.2006.12.1405.CrossRefPubMed

51.

Tasso R, Gaetani M, Molino E, Cattaneo A, Monticone M, Bachi A, et al. The role of bFGF on the ability of MSC to activate endogenous regenerative mechanisms in an ectopic bone formation model. Biomaterials. 2012;33(7):2086–96. doi:10.1016/j.biomaterials.2011.11.043.CrossRefPubMed

52.

Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64(12):1292–309. doi:10.1016/j.addr.2012.01.016.PubMedCentralCrossRefPubMed

53.

Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in tissue engineering. Biomaterials. 2010;31(24):6279–308. doi:10.1016/j.biomaterials.2010.04.053.CrossRefPubMed

54.

Rice R, Rice DP, Thesleff I. Foxc1 integrates Fgf and Bmp signalling independently of twist or noggin during calvarial bone development. Dev Dyn. 2005;233(3):847–52. doi:10.1002/dvdy.20430.CrossRefPubMed

55.

Westhauser F, Zimmermann G, Moghaddam S, Bruckner T, Schmidmaier G, Biglari B, et al. Reaming in treatment of non-unions in long bones: cytokine expression course as a tool for evaluation of non-union therapy. Arch Orthop Trauma Surg. 2015;135(8):1107–16. doi:10.1007/s00402-015-2253-3.CrossRefPubMed

Title: Non-unions treated with bone morphogenic protein 7: introducing the quantitative measurement of human serum cytokine levels as promising tool in evaluation of adjunct non-union therapy
Authors: Arash Moghaddam
Lisa Breier
Patrick Haubruck
Daniel Bender
Bahram Biglari
Andreas Wentzensen
Gerald Zimmermann
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Inflammation / Issue 1/2016
Electronic ISSN: 1476-9255
DOI: https://doi.org/10.1186/s12950-016-0111-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Non-unions treated with bone morphogenic protein 7: introducing the quantitative measurement of human serum cytokine levels as promising tool in evaluation of adjunct non-union therapy

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Cardiovascular diseases-related GNB3 C825T polymorphism has a significant sex-specific effect on serum soluble E-selectin levels

The effect of high glucose on the inhibitory action of C21, a selective AT2R agonist, of LPS-stimulated tissue factor expression in human mononuclear cells

Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study

Role of goblet cell protein CLCA1 in murine DSS colitis

ERK2 and Akt are negative regulators of insulin and Tumor Necrosis Factor-α stimulated VCAM-1 expression in rat aorta endothelial cells

Riboflavin along with antibiotics balances reactive oxygen species and inflammatory cytokines and controls Staphylococcus aureus infection by boosting murine macrophage function and regulates inflammation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page